Our Company

Company Overview

TianTi Biotherapeutics is a preclinical stage biotech company. Our solutions are driven by rigorous data and teamwork. As a next-generation technology company for therapeutic antibodies, we are pioneering a, entirely new approach. By combining proprietary single-cell microfluidics with our yeast display system, we are fundamentally changing the way antibodies are made. This breakthrough work, along with our multidisciplinary teams and industry collaborations, is paving the way for visionary new medicines across the globe.

TianTi Bio has footholds in China and the US.

Our Vision

To innovate the most advanced antibody discovery technology, making new courses of treatment possible for medically challenging diseases.

Our Values

Our values are simple yet central to who we are and how we work. We value innovation, integrity, exceptional work, and humility.

The TianTi Bio Team

Dr. Greg Li, CEO, President, Co-founder

Dr. Li, Co-Founder, is the President, Chief Executive Officer and Chair of the Board of Directors of TianTi Biotherapeutics. Dr. Li work spans from big pharmas such as Pfizer and biotechs including Abpro Labs and Prothera Biologics. Dr. Li’s has worked in both scientific and business development functions bringing him to his current leadership role at TianTi Biotherapeutics.

Dr. Li’s academic background includes research at the Cleveland Clinic where he investigated RNase L role in antiviral and anti-tumor. At Case Western Reserve University Dr. Li researched cytokine signaling in hematopoietic stem cells and leukemia. His tenure at Boston's Children’s Hospital was focused on research using technologies from genetics, immunology, cell biology and imaging to define the role of bone stroma component in normal and abnormal hematopoiesis. Dr. Li holds a PhD from Case Western University and a BS from Wuhan University.

Researching diseases with limited options is challenging.
We provide new possibilities.